| Clinically isolated syndrome
Aubagio vs Ocrevus
Side-by-side clinical, coverage, and cost comparison for clinically isolated syndrome.Deep comparison between: Aubagio vs Ocrevus with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsOcrevus has a higher rate of injection site reactions vs Aubagio based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Ocrevus but not Aubagio, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Aubagio
Ocrevus
At A Glance
Oral
Daily
Pyrimidine synthesis inhibitor
IV infusion
Every 6 months
CD20 antagonist
Indications
- Multiple Sclerosis, Secondary Progressive
- Clinically isolated syndrome
- Clinically isolated syndrome
- Multiple Sclerosis, Relapsing-Remitting
- Multiple Sclerosis, Primary Progressive
Dosing
Multiple Sclerosis, Secondary Progressive, Clinically isolated syndrome 7 mg or 14 mg orally once daily; may be taken with or without food.
Clinically isolated syndrome, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive Initial dose: 300 mg IV infusion, followed two weeks later by a second 300 mg IV infusion; subsequent doses: 600 mg IV infusion every 6 months.
Contraindications
- Severe hepatic impairment
- Pregnancy or females of reproductive potential not using effective contraception
- History of hypersensitivity reaction to teriflunomide, leflunomide, or any inactive ingredient (including anaphylaxis, angioedema, or serious skin reactions)
- Coadministration with leflunomide
- Active HBV infection
- History of life-threatening infusion reaction to OCREVUS
Adverse Reactions
Most common (>=2% above placebo) Headache, increased alanine aminotransferase, diarrhea, alopecia, nausea, paresthesia, arthralgia, neutropenia, hypertension
Serious Hepatotoxicity, bone marrow effects/immunosuppression/infections, hypersensitivity reactions, serious skin reactions, DRESS, cutaneous or mucocutaneous ulcers and impaired wound healing, peripheral neuropathy, increased blood pressure, respiratory effects, pancreatitis (pediatric patients)
Postmarketing Thrombocytopenia, pancreatitis, colitis, drug-induced liver injury, anaphylaxis, angioedema, interstitial lung disease, toxic epidermal necrolysis, Stevens-Johnson syndrome, DRESS, psoriasis (including pustular and nail), nail disorders, cutaneous or mucocutaneous ulcers, impaired wound healing
Most common (>=10%) Upper respiratory tract infections, infusion reactions, skin infections, lower respiratory tract infections
Serious Infusion reactions, infections, progressive multifocal leukoencephalopathy, reduction in immunoglobulins, malignancies, immune-mediated colitis, liver injury
Postmarketing Immune-mediated colitis, liver injury, serious herpes infections, progressive multifocal leukoencephalopathy, babesiosis, pyoderma gangrenosum
Pharmacology
Teriflunomide is an immunomodulatory agent with anti-inflammatory properties that inhibits dihydroorotate dehydrogenase, a mitochondrial enzyme required for de novo pyrimidine synthesis, which may reduce the number of activated lymphocytes in the CNS.
CD20 antagonist; ocrelizumab is a recombinant humanized IgG1 monoclonal antibody that binds to CD20 on pre-B and mature B lymphocytes, resulting in antibody-dependent cellular cytolysis and complement-mediated lysis.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Aubagio
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (4/12)
Ocrevus
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Aubagio
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (1/8)
Ocrevus
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Aubagio
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Ocrevus
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Multiple Sclerosis - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Multiple Sclerosis - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AubagioView full Aubagio profile
OcrevusView full Ocrevus profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.